Page last updated: 2024-11-07

angustmycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

angustmycin A: structure; from Streptomyces hygroscopicus; inhibits GMP synthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121578
CHEMBL ID1444741
CHEBI ID191094
MeSH IDM0059073

Synonyms (41)

Synonym
ai3-50816
adenine, 9-(tetrahydro-3,4-dihydroxy-2-(hydroxymethyl)-5-methylene-2-furyl)-
adenine, 9-(6-deoxy-beta-d-erythro-hex-5-enulofuranosyl)-
9-(tetrahydro-3,4-dihydroxy-2-(hydroxymethyl)-5-methylene-2-furyl)adenine
a 14
9h-purin-6-amine, 9-(6-deoxy-beta-d-erythro-hex-5-en-2-ulofuranosyl)-
9-(6-deoxy-beta-d-erythro-hex-5-enulofuranosyl)adenine
antibiotic a 14
angustmycin a
u-7984
decoyinine ,
(2r,3r,4s)-2-(6-aminopurin-9-yl)-2-(hydroxymethyl)-5-methylene-tetrahydrofuran-3,4-diol
9-(6-deoxy-beta-d-erythro-hex-5-en-2-ulofuranosyl)-9h-purin-6-amine
decomycin, u-7984, ai3-50816, angustmycin a
decoyinin
2004-04-8
BSPBIO_000989
NCGC00163442-01
NCGC00163442-02
NCGC00163442-03
HMS1990A11
u 7984
HMS1792A11
2-(6-aminopurin-9-yl)-2-(hydroxymethyl)-5-methylideneoxolane-3,4-diol
CHEBI:191094
(2r,3r,4s)-2-(6-aminopurin-9-yl)-2-(hydroxymethyl)-5-methylideneoxolane-3,4-diol
CHEMBL1444741
decoyinine (u-7984)
CCG-208190
HMS3403A11
DTXSID50173859
sr-05000002354
SR-05000002354-2
J-012970
CS-0021954
HY-101835
adenosine, 4',5'-didehydro-1'-c-(hydroxymethyl)-
EX-A3232
bdbm50519498
(2r,3r,4s)-2-(6-amino-9h-purin-9-yl)-2-(hydroxymethyl)-5-methylideneoxolane-3,4-diol
AKOS040741619

Research Excerpts

Effects

ExcerptReferenceRelevance
"Angustmycin A has anti-mycobacterial and cytokinin activities, and contains an intriguing structure in which an unusual sugar with C5'-C6' dehydration is linked to adenine via an N-glycosidic bond. "( Efficient biosynthesis of nucleoside cytokinin angustmycin A containing an unusual sugar system.
Cai, YS; Chen, W; Deng, Z; Jiang, M; Ma, H; Price, NPJ; She, Y; Yu, L; Zhou, W, 2021
)
2.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
6-aminopurinesAny compound having 6-aminopurine (adenine) as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocerebrosidaseHomo sapiens (human)Potency7.94330.01268.156944.6684AID2101
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
GMP biosynthetic processGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
GMP biosynthetic processGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
glutamine metabolic processGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
purine nucleobase biosynthetic processGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
purine ribonucleoside monophosphate biosynthetic processGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
GMP synthase activityGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
GMP synthase (glutamine-hydrolyzing) activityGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
ATP bindingGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
cytosolGMP synthase [glutamine-hydrolyzing] Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1578765Inhibition of human GMP synthase2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (37.21)18.7374
1990's10 (23.26)18.2507
2000's9 (20.93)29.6817
2010's5 (11.63)24.3611
2020's3 (6.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.83 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]